Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)

Price, DavidHenley, WilliamCarter, VictoriaSkinner, DerekVella, RebeccaPapi, AlbertoFabbri, Leonardo MKerstjens, Huib AMRoche, NicolasSingh, DaveVogelmeier, Claus FŞen, ElifDelfini Cançado, José EduardoNudo, ElenaBarile, SaraGeorges, George2024-08-142024-08-142021-09-05Price, D, Henley, W, Carter, V, Skinner, D, Vella, R, Papi, A, Fabbri, L M, Kerstjens, H AM, Roche, N, Singh, D, Vogelmeier, C F, Şen, E, Delfini Cançado, J E, Nudo, E, Barile, S & Georges, G 2021, 'Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)', European Respiratory Journal, vol. 58, no. Suppl. 65, PA560. https://doi.org/10.1183/13993003.congress-2021.PA5600903-1936https://hdl.handle.net/2164/24033101041engR MedicineRPneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)Journal item10.1183/13993003.congress-2021.PA56058